Stem Cells and Vaccines in Biomanufacturing
November 2009. Dr Majid Mehtali, at the time CSO of Vivalis gives a personal perspective on demand for stem cell application, in particular in biomanufacturing. In the exclusive interview with B2Bioworld he outlines Vivalis’ expansion strategies and answers questions on financing and cash burn.
In May 2013 Vivalis merged with Austrian Intercell and formed Valneva SE which significantly changed the group’s strategy. However the approach to biomanufacturing of vaccines remains. Updated 2013Reading time: 8 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Bayer AG: New stakes in stem cells
Andreas Busch, Head of Global Drug Discovery on results, technology platforms, and expectations
Stem Cell Research Now and in the Future - Viewed from GSK
Sir Patrick Vallance, at the time President Pharmaceuticals, R&D of GlaxoSmithKline
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Stem Cells – Failings and Deliveries
Novartis and Stem Cells
Mark Fishman, President Novartis Institutescomments on the company’s strategy and technology acquisitions in the field
Patenting Stem Cells – Behind the Front Stages
A legal approach solving problems with patentability